Ontology highlight
ABSTRACT:
SUBMITTER: Asami K
PROVIDER: S-EPMC4129529 | biostudies-literature | 2014 Oct
REPOSITORIES: biostudies-literature
Asami Kazuhiro K Atagi Shinji S
World journal of clinical oncology 20141001 4
First-generation epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs), including gefitinib and erlotinib, have proven to be highly effective agents for advanced non-small cell lung cancer (NSCLC) in patients harboring an activating EGFR mutation such as the exon 19 deletion mutation and L858R. Although those reversible small molecular targeted agents provide a significant response and survival benefit, all responders eventually acquire resistance. Second-generation EGFR-target ...[more]